Nutricosmetic is the point at which nutrition and cosmetics meet. The term encompasses the beneficial effects on beauty resulting from consuming nutrients through the use of food supplements.
The global Nutricosmetics market has experienced massive growth in the past few years. Its importance has significantly increased, as consumers are seeking natural ingredients that promote beauty from the inside out. Ingesting nutrients or active ingredients is a new addition to the beauty routine, whose function is to nourish skin, hair, and nails.
Growing concern for personal care and rising awareness among consumers about the side effects of cosmetic ingredients on their health are key factors driving the global nutricosmetics market. The concerns regarding the side effects of chemical components in a product is propelling people to look for a natural alternative.
According to Future market insights (FMI), the global nutricosmetics market is expected to have a sustainable and steady growth over the forecast period 2020-2030 with a CAGR of above 8%. With the growing demand witnessed across the world, the global market value of nutricosmetics is projected to double the current value by the end of 2030.
Sales of nutricosmetics dipped in 2020 on account of COVID-19 impact; however, the long-term outlook on the market remains bullish.
North America is one of the leading markets for Nutricosmetics. It is expected to cover nearly 1/5th of the global nutricosmetics market by the end of the forecast period 2020-2030.
Market in Europe is seeing an upward growth thanks to the changing lifestyles of the consumers in the region. This growth is expected to continue over the forecast period 2020-2030 as people are adapting to the new way of personal care and beauty enhancement using nutricosmetics.
By 2026, the Nutricosmetics market could potentially reach € 8.8 billion.
Reference:
Nutricosmetics Market Outlook and Opportunity Analysis 2030 | Future Market Insights
Nutricosmetics: The New Beauty Routine – Nexira
A significant uptick in M&A activity in the biosimilars sector is being driven by FDA regulatory reforms, a maturing patent litigation framework and a looming patent cliff — $200 billion of branded products are facing patent expiration by 2030.
The Drewry World Container Index edged lower this week as falling Asia-Europe rates outweighed firmer pricing on the Transpacific, with carriers preparing another round of blank sailings ahead of China’s Golden Week holiday.
On 14 July 2026, the European Parliamentary Research Service (EPRS) published a comprehensive briefing on PFAS (per- and polyfluoroalkyl substances), also known as ‘forever chemicals’. The document is intended to serve as a technical basis for MEPs in their upcoming political decisions on PFAS regulation and summarises the current state of scientific knowledge, regulation and procedures.
Following a series of typhoon disruptions in East China during the month of August, major ports including Shanghai and Ningbo continue to experience congestion and operational recovery challenges. Industry reports indicate that vessel schedules, yard operations, and equipment circulation remain affected as terminals work through accumulated backlogs from successive storm events.
Under REACH Annex XVII Entry 78, the EU has banned the placing on the market of synthetic polymer microparticles (SPMs) unless a specific derogation applies. Derogations exist for essential uses such as:
As a result of the amendment of the CLP Regulation (Regulation (EC) No 1272/2008 on the classification, labelling and packaging of substances and mixtures), new hazard classes have entered into force.
In a converging policy shift on both sides of the Atlantic, European regulators this week published a roadmap toward fully replacing animal testing for chemical safety assessments, while the US Environmental Protection Agency issued a rare update to its list of alternative test methods.
The global pharmaceutical fine chemicals sector is undergoing a profound transformation, with India emerging as a central growth engine amid sweeping changes in supply chain strategies and regulatory priorities. As drug makers and contract manufacturers adapt to stricter oversight and evolving sourcing preferences, the industry’s focus is shifting rapidly from cost efficiency to compliance, localisation and technical sophistication.
Stakeholders are being encouraged to weigh in on the European Chemicals Agency (ECHA) 60-day public consultation period related to a planned ban on per-and-polyfluoroalkyl (PFAS) substances, also known as forever chemicals.